See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
PRA Group, Inc. (PRAA) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PRA Group, Inc. (PRAA) - free report >>
Image: Bigstock
New Strong Sell Stocks for March 6th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals. The Zacks Consensus Estimate for its current year earnings has been revised 7.6% downward over the last 30 days.
Compass Diversified Holdings LLC (CODI - Free Report) provides public investors with an opportunity to participate in the ownership and growth of companies. The Zacks Consensus Estimate for its current year earnings has been revised 3.6% downward over the last 30 days.
Eagle Pharmaceuticals, Inc. (EGRX - Free Report) is a specialty pharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 8.8% downward over the last 30 days.
Impax Laboratories, Inc. is a specialty pharmaceutical company engaged in the development and marketing of bioequivalent pharmaceutical products. The Zacks Consensus Estimate for its current year earnings has been revised 18.1% downward over the last 30 days.
PRA Group, Inc. (PRAA - Free Report) is a financial and business service company. The Zacks Consensus Estimate for its current year earnings has been revised 19.7% downward over the last 30 days.
View the entire Zacks Rank #5 List.